» Authors » Daniela Bota

Daniela Bota

Explore the profile of Daniela Bota including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 13
Citations 217
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Rehne Jensen L, Maier A, Lomstein A, Graillon T, Hrachova M, Bota D, et al.
Neurosurg Rev . 2022 Aug; 45(5):3067-3081. PMID: 35984552
Treatment-refractory meningiomas have a dismal prognosis and limited treatment options. Meningiomas express high-densities of somatostatin receptors (SSTR), thus potentially susceptible to antitumorigenic effects of somatostatin analogues (SSA). Evidence for SSA...
2.
Du S, Bota D, Kong X
Neurol Int . 2022 Jul; 14(3):574-580. PMID: 35893281
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive disease that originates from lymphocytes and develops in the central nervous system. There is no standard consolidation/maintenance therapy for...
3.
Chang S, Singh L, Thaker K, Abedi S, Singh M, Patel T, et al.
Int J Mol Sci . 2022 Jun; 23(12). PMID: 35743133
The aim of this study was to determine the role of retrograde signaling (mitochondria to nucleus) in MCF7 breast cancer cells. Therefore, in the present study, MCF7-H and MCF7-J cybrids...
4.
Chow D, Glavis-Bloom J, Soun J, Weinberg B, Loveless T, Xie X, et al.
PLoS One . 2020 Dec; 15(12):e0242953. PMID: 33296357
Background: The rapid spread of coronavirus disease 2019 (COVID-19) revealed significant constraints in critical care capacity. In anticipation of subsequent waves, reliable prediction of disease severity is essential for critical...
5.
Cloughesy T, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, et al.
JAMA Oncol . 2020 Oct; 6(12):1939-1946. PMID: 33119048
Importance: New treatments are needed to improve the prognosis of patients with recurrent high-grade glioma. Objective: To compare overall survival for patients receiving tumor resection followed by vocimagene amiretrorepvec (Toca...
6.
Abedi S, Yung G, Atilano S, Thaker K, Chang S, Chwa M, et al.
PeerJ . 2020 Oct; 8:e9908. PMID: 33062421
Background: Drug therapy yields different results depending on its recipient population. Cisplatin, a commonly used chemotherapeutic agent, causes different levels of resistance and side effects for different patients, but the...
7.
Mirian C, Duun-Henriksen A, Maier A, Pedersen M, Rehne Jensen L, Bashir A, et al.
J Nucl Med . 2020 Aug; 62(4):507-513. PMID: 32859705
Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas. We performed an individual patient data meta-analysis, including all published data on meningioma patients treated...
8.
Patel T, Norman L, Chang S, Abedi S, Liu C, Chwa M, et al.
Front Oncol . 2019 Aug; 9:640. PMID: 31380278
Cisplatin, a powerful antitumor agent, causes formation of DNA adducts, and activation of apoptotic pathways. Presently, cisplatin resistance develops in up to 70% of patients but the underlying molecular mechanism(s)...
9.
Shaver M, Kohanteb P, Chiou C, Bardis M, Chantaduly C, Bota D, et al.
Cancers (Basel) . 2019 Jun; 11(6). PMID: 31207930
Radiographic assessment with magnetic resonance imaging (MRI) is widely used to characterize gliomas, which represent 80% of all primary malignant brain tumors. Unfortunately, glioma biology is marked by heterogeneous angiogenesis,...
10.
Wang A, Jamshidi A, Oh N, Sahyouni R, Nowroozizadeh B, Kim R, et al.
Front Neurol . 2018 Nov; 9:919. PMID: 30416484
Multiple intracranial meningiomas account for <10% of all meningiomas. Familial multiple meningiomas have been linked to germline mutations in two genes: (NF2) and (SMARCB1). Sporadic multiple meningiomas have been associated...